Published online before print March 25, 2004, doi: 10.1161/01.RES.0000126569.75419.74
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Report |
Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress
From the Whitaker Cardiovascular Institute and Amyloid Treatment and Research Program, Evans Department of Medicine, Boston University School of Medicine, Boston, Mass.
Correspondence to Dr Ronglih Liao, Boston University School of Medicine, 650 Albany St, X-720, Boston, MA 02118. E-mail rliao{at}bu.edu
Abstract
Primary amyloidosis is a systemic disorder characterized by the clonal production and tissue deposition of immunoglobulin light chain (LC) proteins. Congestive heart failure remains the greatest cause of death in primary amyloidosis, due to the development of a rapidly progressive amyloid cardiomyopathy. Amyloid cardiomyopathy is largely unresponsive to current heart failure therapies, and is associated with a median survival of less than 6 months and a 5-year survival of less than 10%. The mechanisms underlying this disorder, however, remain unknown. In this report, we demonstrate that physiological levels of human amyloid LC proteins, isolated from patients with amyloid cardiomyopathy (cardiac-LC), specifically alter cellular redox state in isolated cardiomyocytes, marked by an increase in intracellular reactive oxygen species and upregulation of the redox-sensitive protein, heme oxygenase-1. In contrast, vehicle or control LC proteins isolated from patients without cardiac involvement did not alter cardiomyocyte redox status. Oxidant stress imposed by cardiac-LC proteins further resulted in direct impairment of cardiomyocyte contractility and relaxation, associated with alterations in intracellular calcium handling. Cardiomyocyte dysfunction induced by cardiac-LC proteins was independent of neurohormonal stimulants, vascular factors, or extracellular fibril deposition, and was prevented through treatment with a superoxide dismutase/catalase mimetic. This study suggests that cardiac dysfunction in amyloid cardiomyopathy is directly mediated by LC protein-induced cardiomyocyte oxidant stress and alterations in cellular redox status, independent of fibril deposition. Antioxidant therapies or treatment strategies aimed at eliminating circulating LC proteins may therefore be beneficial in the treatment of this fatal disease.
Key Words: amyloid cardiomyopathy • cardiomyocyte physiology • oxidant stress
This article has been cited by other articles:
 |
|
 |
|
  N. Ardanaz, X.-P. Yang, M. E. Cifuentes, M. J. Haurani, K. W. Jackson, T.-D. Liao, O. A. Carretero, and P. J. Pagano Lack of Glutathione Peroxidase 1 Accelerates Cardiac-Specific Hypertrophy and Dysfunction in Angiotensin II Hypertension Hypertension, January 1, 2010; 55(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Comenzo How I treat amyloidosis Blood, October 8, 2009; 114(15): 3147 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rapezzi, G. Merlini, C. C. Quarta, L. Riva, S. Longhi, O. Leone, F. Salvi, P. Ciliberti, F. Pastorelli, E. Biagini, et al. Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types Circulation, September 29, 2009; 120(13): 1203 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Girnius, D. C. Seldin, M. Skinner, K. T. Finn, K. Quillen, G. Doros, and V. Sanchorawala Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease Haematologica, July 1, 2009; 94(7): 1029 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feng, I. S. Syed, M. Martinez, J. K. Oh, A. S. Jaffe, M. Grogan, W. D. Edwards, M. A. Gertz, and K. W. Klarich Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis Circulation, May 12, 2009; 119(18): 2490 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A SEEGER, B KLUMPP, U KRAMER, N I STAUDER, M FENCHEL, C D CLAUSSEN, and S MILLER MRI assessment of cardiac amyloidosis: experience of six cases with review of the current literature Br. J. Radiol., April 1, 2009; 82(976): 337 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Dember Modern Treatment of Amyloidosis: Unresolved Questions J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Bryce, R. P. Ketterling, M. A. Gertz, M. Lacy, R. A. Knudson, S. Zeldenrust, S. Kumar, S. Hayman, F. Buadi, R. A. Kyle, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica, March 1, 2009; 94(3): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Bellavia, P A Pellikka, T P Abraham, G B Al-Zahrani, A Dispenzieri, J K Oh, R E Espinosa, C G Scott, C Miyazaki, and F A Miller 'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis Heart, February 1, 2009; 95(3): 234 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition Circ Heart Fail, November 1, 2008; 1(4): 249 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, and K. Zervas Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study Ann. Onc., October 1, 2008; 19(10): 1765 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Arendt, M. Ramirez-Alvarado, L. A. Sikkink, J. J. Keats, G. J. Ahmann, A. Dispenzieri, R. Fonseca, R. P. Ketterling, R. A. Knudson, E. M. Mulvihill, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2 Blood, September 1, 2008; 112(5): 1931 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lavatelli, D. H. Perlman, B. Spencer, T. Prokaeva, M. E. McComb, R. Theberge, L. H. Connors, V. Bellotti, D. C. Seldin, G. Merlini, et al. Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue Mol. Cell. Proteomics, August 1, 2008; 7(8): 1570 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feng, W. D. Edwards, J. K. Oh, K. Chandrasekaran, M. Grogan, M. W. Martinez, I. I. Syed, D. A. Hughes, J. A. Lust, A. S. Jaffe, et al. Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis Circulation, November 20, 2007; 116(21): 2420 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Modesto, A. Dispenzieri, M. Gertz, S. A. Cauduro, B. K. Khandheria, J. B. Seward, R. Kyle, C. M. Wood, K. R. Bailey, A. J. Tajik, et al. Vascular abnormalities in primary amyloidosis Eur. Heart J., April 12, 2007; (2007) ehm066v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-X. Wang and P. W. Sanders Immunoglobulin Light Chains Generate Hydrogen Peroxide J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1239 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Monis, C. Schultz, R. Ren, J. Eberhard, C. Costello, L. Connors, M. Skinner, and V. Trinkaus-Randall Role of Endocytic Inhibitory Drugs on Internalization of Amyloidogenic Light Chains by Cardiac Fibroblasts Am. J. Pathol., December 1, 2006; 169(6): 1939 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Dember Amyloidosis-Associated Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Shah, Y. Inoue, and M. R. Mehra Amyloidosis and the heart: a comprehensive review. Arch Intern Med, September 25, 2006; 166(17): 1805 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dispenzieri, M. Q. Lacy, J. A. Katzmann, S. V. Rajkumar, R. S. Abraham, S. R. Hayman, S. K. Kumar, R. Clark, R. A. Kyle, M. R. Litzow, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood, April 15, 2006; 107(8): 3378 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Dong, X. Zhang, and J. Ren Leptin Regulates Cardiomyocyte Contractile Function Through Endothelin-1 Receptor-NADPH Oxidase Pathway Hypertension, February 1, 2006; 47(2): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Falk Diagnosis and Management of the Cardiac Amyloidoses Circulation, September 27, 2005; 112(13): 2047 - 2060. [Full Text] [PDF]
|
|
|
|
|
|
B. Ng, L. H. Connors, R. Davidoff, M. Skinner, and R. H. Falk Senile Systemic Amyloidosis Presenting With Heart Failure: A Comparison With Light Chain-Associated Amyloidosis Arch Intern Med, June 27, 2005; 165(12): 1425 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Kholova and H W M Niessen Amyloid in the cardiovascular system: a review J. Clin. Pathol., February 1, 2005; 58(2): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Y. Kwong and R. H. Falk Cardiovascular Magnetic Resonance in Cardiac Amyloidosis Circulation, January 18, 2005; 111(2): 122 - 124. [Full Text] [PDF]
|
|
|
|
|
|
V. Trinkaus-Randall, M. T. Walsh, S. Steeves, G. Monis, L. H. Connors, and M. Skinner Cellular Response of Cardiac Fibroblasts to Amyloidogenic Light Chains Am. J. Pathol., January 1, 2005; 166(1): 197 - 208. [Abstract] [Full Text] [PDF]
|
|